{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:35:30Z","timestamp":1794119730319,"version":"4.8.0"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004920","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000}}],"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["757699"],"award-info":[{"award-number":["757699"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["757699"],"award-info":[{"award-number":["757699"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["757699"],"award-info":[{"award-number":["757699"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Estimating the proportion of individuals currently infected with\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      (\n                      <jats:italic>Mtb<\/jats:italic>\n                      ) is key for informing global health policies. Although a substantial portion of the global population exhibit tuberculous immunoreactivity, not all have a viable\n                      <jats:italic>Mtb<\/jats:italic>\n                      infection. Moreover, individuals with recent infections are at a higher risk of developing tuberculosis (TB). Here, we present estimates of the global burden of viable\n                      <jats:italic>Mtb<\/jats:italic>\n                      infection, using new insights into the natural history of TB.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      We constructed country-specific trends in annual risk of infection considering estimates of TB burden, immunoreactivity reversion, and age-specific mixing. We applied these trends to a deterministic mathematical model incorporating reinfection and self-clearance to estimate recent (within 2 years) and total viable\n                      <jats:italic>Mtb<\/jats:italic>\n                      infections. Empirical data on self-clearance are limited, so rates were informed by modelling estimates. In 2022, we estimated that 133.7 million people (95% uncertainty interval [UI]: 104.0, 171.1) had a recent\n                      <jats:italic>Mtb<\/jats:italic>\n                      infection, representing 1.7% (95% UI: 1.3, 2.2) of the global population. In total, 288.9 million people (95% UI: 242.2, 342.7)\u2014or 3.7% (95% UI: 3.1, 4.3) globally\u2014were estimated to harbour a viable\n                      <jats:italic>Mtb<\/jats:italic>\n                      infection. Among those recently infected, 12.0% (95% UI: 11.4, 12.7) were children under 15 years of age. Most recent infections were found in the World Health Organization regions of South-East Asia (49.0%; 95% UI: 37.2, 62.4), the Western Pacific (19.7%; 95% UI: 12.6, 30.5), and Africa (17.9%; 95% UI: 12.9, 24.1). India, Indonesia, and China had the highest burden, with 39.1 million (95% UI: 18.0, 73.6), 12.0 million (95% UI: 5.8, 22.9), and 11.2 million (95% UI: 5.0, 25.5) people, respectively, recently infected with\n                      <jats:italic>Mtb<\/jats:italic>\n                      . Sensitivity analyses of varying self-clearance scenarios showed significant changes in global estimates of viable\n                      <jats:italic>Mtb<\/jats:italic>\n                      infection, particularly in total burden, with lower self-clearance rates. Overall uncertainty in the estimates was considerable, reflecting limitations in the underlying data informing key model parameters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our findings offer global burden estimates of viable\n                      <jats:italic>Mtb<\/jats:italic>\n                      infection and reveal a sizable population recently infected with\n                      <jats:italic>Mtb<\/jats:italic>\n                      and at high risk of progression to disease. New diagnostic tools that can detect individuals with viable\n                      <jats:italic>Mtb<\/jats:italic>\n                      \u2014particularly those who would benefit from TB preventive therapy\u2014are urgently needed.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004920","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T18:47:07Z","timestamp":1770317227000},"page":"e1004920","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Estimating the global burden of viable Mycobacterium tuberculosis infection: A mathematical modelling study"],"prefix":"10.1371","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6518-9719","authenticated-orcid":true,"given":"Alvaro","family":"Schwalb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5825-9347","authenticated-orcid":true,"given":"Peter J.","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3502-0744","authenticated-orcid":true,"given":"Hannah M.","family":"Rickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2833-9087","authenticated-orcid":true,"given":"C\u00e9sar A.","family":"Ugarte-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7542-4065","authenticated-orcid":true,"given":"Katherine C.","family":"Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4132-7467","authenticated-orcid":true,"given":"Rein M. G. J.","family":"Houben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"5","key":"pmed.1004920.ref001","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41564-024-01683-0","article-title":"Rethinking the burden of latent tuberculosis to reprioritize research","volume":"9","author":"MA Behr","year":"2024","journal-title":"Nat Microbiol"},{"key":"pmed.1004920.ref002","volume-title":"The end TB strategy","author":"World Health Organization","year":"2015"},{"issue":"7","key":"pmed.1004920.ref003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0003306","article-title":"Optimizing the cascade of prevention to protect people from tuberculosis: a potential game changer for reducing global tuberculosis incidence","volume":"4","author":"A Matteelli","year":"2024","journal-title":"PLOS Glob Public Health"},{"key":"pmed.1004920.ref004","article-title":"Revisiting the timetable of tuberculosis","volume":"362","author":"MA Behr","year":"2018","journal-title":"BMJ"},{"issue":"7","key":"pmed.1004920.ref005","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.282.7.677","article-title":"Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project","volume":"282","author":"C Dye","year":"1999","journal-title":"JAMA"},{"issue":"10","key":"pmed.1004920.ref006","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","volume":"13","author":"RMGJ Houben","year":"2016","journal-title":"PLoS Med"},{"key":"pmed.1004920.ref007","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S1473-3099(18)30625-X","article-title":"Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study","volume":"18","author":"Collaborators GBD Tuberculosis","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"pmed.1004920.ref008","article-title":"Is Mycobacterium tuberculosis infection life long?","volume":"367","author":"MA Behr","year":"2019","journal-title":"BMJ"},{"issue":"1943","key":"pmed.1004920.ref009","first-page":"20201635","article-title":"Self-clearance of Mycobacterium tuberculosis infection: implications for lifetime risk and population at-risk of tuberculosis disease","volume":"288","author":"JC Emery","year":"2021","journal-title":"Proc Biol Sci"},{"issue":"47","key":"pmed.1004920.ref010","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2221186120","article-title":"Reevaluating progression and pathways following Mycobacterium tuberculosis infection within the spectrum of tuberculosis","volume":"120","author":"KC Horton","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"pmed.1004920.ref011","first-page":"503","article-title":"Annual risk of tuberculous infection. 1988","volume":"80","author":"GM Cauthen","year":"2002","journal-title":"Bull World Health Organ"},{"issue":"173","key":"pmed.1004920.ref012","doi-asserted-by":"crossref","first-page":"240007","DOI":"10.1183\/16000617.0007-2024","article-title":"Overlooked, dismissed, and downplayed: reversion of Mycobacterium tuberculosis immunoreactivity","volume":"33","author":"KD Dale","year":"2024","journal-title":"Eur Respir Rev"},{"issue":"12","key":"pmed.1004920.ref013","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1093\/aje\/kwad028","article-title":"Impact of reversion of Mycobacterium tuberculosis immunoreactivity tests on the estimated annual risk of tuberculosis infection","volume":"192","author":"A Schwalb","year":"2023","journal-title":"Am J Epidemiol"},{"issue":"9","key":"pmed.1004920.ref014","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(22)00448-0","article-title":"Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?","volume":"22","author":"DW Dowdy","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"pmed.1004920.ref015","first-page":"156","article-title":"Age- and sex-specific social contact patterns and incidence of Mycobacterium tuberculosis Infection","volume":"183","author":"PJ Dodd","year":"2016","journal-title":"Am J Epidemiol"},{"key":"pmed.1004920.ref016","first-page":"28","article-title":"Controlled chemoprophylaxis trials in tuberculosis. A general review","volume":"26","author":"SH Ferebee","year":"1970","journal-title":"Bibl Tuberc"},{"key":"pmed.1004920.ref017","first-page":"1","article-title":"Tubercule bacilli in latent tuberculosis lesions and in lung tissue without tuberculosis lesions","volume":"4","author":"EL Opie","year":"1927","journal-title":"Arch Pathol"},{"key":"pmed.1004920.ref018","author":"World Health Organization","year":"2023"},{"key":"pmed.1004920.ref019","article-title":"Projecting contact matrices in 177 geographical regions: an update and comparison with empirical data for the COVID-19 era","volume":"17","author":"Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group","year":"2021","journal-title":"PLoS Comput Biol"},{"issue":"6","key":"pmed.1004920.ref020","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S2213-2600(24)00028-6","article-title":"Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise","volume":"12","author":"AK Coussens","year":"2024","journal-title":"Lancet Respir Med"},{"key":"pmed.1004920.ref021","unstructured":"Stan Development Team. Stan Modeling Language Users Guide and Reference Manual, v2.35. 2024. Available from: https:\/\/mc-stan.org"},{"key":"pmed.1004920.ref022","author":"RCore Team","year":"2024"},{"issue":"6","key":"pmed.1004920.ref023","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/cir951","article-title":"Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis","volume":"54","author":"JR Andrews","year":"2012","journal-title":"Clin Infect Dis"},{"key":"pmed.1004920.ref024","unstructured":"United Nations. World population prospects\u2014population division. In: World population prospects; 2022 [Internet]. [cited Jun 2023]. Available from: https:\/\/population.un.org\/wpp\/"},{"issue":"10062","key":"pmed.1004920.ref025","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)30388-9","article-title":"Guidelines for accurate and transparent health estimates reporting: the GATHER statement","volume":"388","author":"GA Stevens","year":"2016","journal-title":"Lancet"},{"key":"pmed.1004920.ref026","volume-title":"WHO global lists of high burden countries for tuberculosis (TB), TB\/HIV and multidrug\/rifampicin-resistant TB (MDR\/RR-TB), 2021-2025: background document","author":"World Health Organization","year":"2021"},{"issue":"22","key":"pmed.1004920.ref027","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","article-title":"Latent Mycobacterium tuberculosis infection","volume":"372","author":"H Getahun","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"pmed.1004920.ref028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096613","article-title":"Tuberculin skin test reversion following isoniazid preventive therapy reflects diversity of immune response to primary Mycobacterium tuberculosis infection","volume":"9","author":"DF Johnson","year":"2014","journal-title":"PLoS One"},{"key":"pmed.1004920.ref029","doi-asserted-by":"crossref","first-page":"101815","DOI":"10.1016\/j.eclinm.2022.101815","article-title":"Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis","volume":"56","author":"Y Hamada","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"6","key":"pmed.1004920.ref030","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(21)00043-4","article-title":"Detection of Mycobacterium tuberculosis complex DNA in CD34-positive peripheral blood mononuclear cells of asymptomatic tuberculosis contacts: an observational study","volume":"2","author":"M Belay","year":"2021","journal-title":"Lancet Microbe"},{"issue":"3","key":"pmed.1004920.ref031","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1473-3099(20)30914-2","article-title":"Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial","volume":"21","author":"TJ Scriba","year":"2021","journal-title":"Lancet Infect Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004920","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:48:06Z","timestamp":1770835686000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004920"}},"subtitle":[],"editor":[{"given":"Madhukar","family":"Pai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004920","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]}}}